Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review

References

• Cancer Facts & Figures 2015. Atlanta, GA, USA: The American Cancer Society, 2015
   Google Scholar
• Ng CS, Wood CG, Silverman PM, et al. Renal cell carcinoma: diagnosis, staging, and surveillance. Am J Roentgenol 2008;191:1220-32
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009;7:618-30
   PubMed Web of Science ®Google Scholar
• Chin AI, Lam JS, Figlin RA, et al. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol 2006;8:1-7
   PubMedGoogle Scholar
• Lam JS, Leppert JT, Belldegrun AS, et al. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23:202-12
   PubMed Web of Science ®Google Scholar
• Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:193-205
   PubMed Web of Science ®Google Scholar
• Buti S, Bersanelli M, Sikokis A, et al. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 2013;24:535-54
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
   PubMed Web of Science ®Google Scholar
• Patil S, Manola J, Elson P, et al. Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol 2012;188:2095-100
   PubMed Web of Science ®Google Scholar
• Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol 2012;24:284-90
   PubMed Web of Science ®Google Scholar
• Oudard S, Elaidi RT. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev 2012;38:981-7
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (London, England) 2011;378:1931-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552-62
   PubMed Web of Science ®Google Scholar
• Heng DY, Signorovitch J, Swallow E, et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies. PLoS One 2014;9:e114264
   PubMed Web of Science ®Google Scholar
• Ko JJ, Choueiri TK, Rini BI, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Canc 2014:1-6
   Web of Science ®Google Scholar
• Patel SB, Tantravahi SK, Gill D, et al. Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma. 2015 Genitourinary Cancers Symposium. J Clin Oncol 2015;33(Suppl 7):abstr 495
   Web of Science ®Google Scholar
• Escudier B, Michaelson MD, Motzer RJ, et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Canc 2014;110:2821-8
   PubMed Web of Science ®Google Scholar
• Escudier B, Motzer RJ, Lim HY, et al. Safety and efficacy of second-line axitinib versus sorafenib in metastatic renal cell carcinoma by duration of prior therapy: subanalyses from a phase III trial. European Cancer Congress 2013, Genitourinary Malignancies – Other. 27 September–1 October 2013, Amsterdam, Netherlands. Eur J Canc2013
   PubMed Web of Science ®Google Scholar
• Ruiz AL, Bolos MV, Viqueira A, et al. Outcome of metastatic renal cell carcinoma (mRCC) patients in the era of new targeted therapies. 2013 European Society for Medical Oncology, 26–30 September 2013, Madrid, Spain
   Google Scholar
• Elaidi RT, Harbaoui AH, Beuselinck B, et al. What is the best treatment option for second-line in long-responders to the first line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI–TKI or TKI–mTORi? Final results of a European retrospective study. European Society for Medical Oncology, 26–30 September 2013, Madrid, Spain
   Google Scholar
• Sherman SA, Wang X, Amzal B, et al. A weighted-adjusted indirect comparison of everolimus (EVE) versus axitinib (AXI) in second-line metastatic renal cell carcinoma (mRCC) patients who previously failed sunitinib therapy. Genitourinary Cancers Symposium. J Clin Oncol2014;32(Suppl 4):abstr 491
   Web of Science ®Google Scholar
• Wong MK, Yang H, Signorovitch JE, et al. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. Curr Med Res Opin 2014;30:537-45
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Vogelzang NJ, Pal SK, et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin 2014;30:2343-53
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814-23
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13
   PubMed Web of Science ®Google Scholar